Recent weeks have seen renewed focus on the future of the UK’s life sciences sector, a sector rightly recognised as one of our greatest national assets, yet one that continues to face deep and growing structural challenges.
The task ahead is clear: we must invest so that UK companies can scale here, stay here, grow here and benefit patients here. While international investors continue to value the strength of our science, our entrepreneurs, and the Government’s commitment to life sciences, the reality is that many promising UK companies remain locked out of growth. Later-stage companies may still attract capital, but early and mid-stage innovators, the very businesses developing the next wave of treatments, diagnostics, and technologies that can improve patient outcomes and NHS efficiency, are being left behind.
As set out in the Bio Industry Association’s open letter to the Chancellor, and reinforced by its Q3 financing data, the UK’s longstanding scale-up funding gap is the critical barrier that continues to undermine our ability to build and retain home-grown UK companies. The BIA’s call for the government to double down on investment, accelerate the flow of Innovate UK and British Business Bank funds, and expand R&D tax reliefs and venture incentives is exactly the kind of decisive action needed to keep innovation and jobs anchored here in the UK.
The House of Lords Science and Technology Committee’s recent report ‘Bleeding to Death: The Science and Technology Growth Emergency’ underscores this crisis. It warns that the UK economy is “bleeding out” due to its failure to scale technology companies, and that without radical reform, the nation risks becoming an “incubator economy”, where breakthroughs developed with UK science and, in some cases, with public funding end up being commercialised abroad. The Lords’ recommendation for a National Council for Science, Technology and Growth is a timely and practical proposal to deliver the leadership and coordination the sector needs to ensure discovery is converted into domestic scale and adoption. Yet these measures will only deliver their full potential if matched by faster routes for proven technologies to reach patients and healthcare systems, turning investment into visible public benefit.
There are some glimmers of hope. For example, the Government’s recent moves to promote UK equity investment, including proposals to introduce UK-focused ISA incentives that channel more tax-advantaged savings into UK-listed companies, are positive signals that domestic capital can be unlocked to back home-grown companies.
But as both the BIA and the House of Lords make clear, time is not on our side. Many companies now operate on cash runways measured in months. Every month of delay and inaction forces hard choices: pausing development, freezing new hires, cutting manufacturing, or moving operations overseas. Once skilled teams disperse and programmes are shelved, those capabilities, and the health and economic benefits they bring, are lost, often permanently.
The life sciences sector doesn’t just deliver treatments and technologies; it delivers high-value jobs, exports, and economic resilience. If we are serious about transforming the NHS, boosting productivity, and driving national growth, then unlocking investment and accelerating adoption so UK innovations can scale at home must be a shared national mission, now, not later.
By Dr Gino Miele, CEO of genedrive plc
